Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeartSciencesHSCSW 18 EV-to-Revenue is 0.00 as of Sep. 10, 2026. GuruFocus rates HSCSW with a GF Score™ of 18/100. The stock has 10 warning signs investors should review. Among 812 Medical Devices & Instruments companies, HeartSciences ranks worse than 99.75% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HeartSciences's enterprise value is $0.00 Mil.
HeartSciences's Revenue for the trailing twelve months (TTM) ended in Apr. 2026 was $0.00 Mil. Therefore, HeartSciences's EV-to-Revenue for today is 0.00.
The historical rank and industry rank for HeartSciences's EV-to-Revenue or its related term are showing as below:
HSCSW'
s EV-to-Revenue Range Over the Past 10 Years
Min: -121.46 Med: 776.71 Max: 5182.28
Current: 5188.75
During the past 7 years, the highest EV-to-Revenue of HeartSciences was 5182.28. The lowest was -121.46. And the median was 776.71.
HSCSW's EV-to-Revenue is ranked worse than 99.75% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 2.945
vs HSCSW: 5188.75
As of today (2026-09-10), HeartSciences's stock price is $0.0706.
HeartSciences's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $0.00. Therefore, HeartSciences's PS Ratio for today is .
HeartSciences's share price for today is $0.0706.
HeartSciences's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeartSciences EV-to-Revenue Related Terms
HeartSciences EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for HeartSciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HSCSW vs IRIX, ALRTF, ADGM: EV-to-Revenue Comparison
For the Medical Devices subindustry, HeartSciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeartSciences EV-to-Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HeartSciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where HeartSciences's EV-to-Revenue falls into.
HeartSciences's current Enterprise Value is $0.00 Mil.
HeartSciences's Revenue for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeartSciences (HSCSW) has a EV-to-Revenue of 0.00 as of Sep. 10, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on HeartSciences and its competitors. According to the industry distribution chart, HeartSciences ranks #810 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 99.8%.
Is HeartSciences' EV-to-Revenue too high?
HeartSciences' current EV-to-Revenue is 0.00. Based on the distribution chart, HeartSciences ranks #810 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, HeartSciences has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does HeartSciences' EV-to-Revenue compare to IRIX and ALRTF?
According to the Medical Devices & Instruments industry distribution chart, HeartSciences ranks #810 out of 812 companies for EV-to-Revenue. This places HeartSciences in the lower half of its industry. The industry median EV-to-Revenue is 2.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Medical Devices & Instruments company?
The median EV-to-Revenue among Medical Devices & Instruments companies is 2.95, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on HeartSciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-Revenue is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeartSciences's current EV-to-Revenue is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeartSciences stock overvalued right now?
HeartSciences (HSCSW) has a current EV-to-Revenue of 0.00. The current EV-to-Revenue is 0.00. HeartSciences' overall GF Score™ is 18/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For HeartSciences (HSCSW), the current EV-to-Revenue is 0.00 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
18GF Score
Get the complete analysis for HSCSW
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HSCSW has been successfully added to your 
